JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB221398

Recombinant human PD1 protein (Fc Chimera Active)

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant human PD1 protein (Fc Chimera Active) is a Human Fragment protein, in the 25 to 167 aa range, expressed in HEK 293 cells, with >95%, < 0.1 EU/g endotoxin level, suitable for SDS-PAGE, FuncS, HPLC.

대체 명칭 보기

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

8 Images
Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Supplier Data

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Loaded Human PD-1, Fc Tag, low endotoxin (HPLC-verified) on Protein A Biosensor, can bind Human PD-L1, His Tag (HPLC & BLI verified) with an affinity constant of 5.3μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Immobilized Biotinylated Human PD-L2, Avitag,His Tag (recommended for biopanning) at 1 µg/mL (100 µL/well) on streptavidin precoated (0.2 µg/well) plate, can bind Human PD-1, Fc Tag, low endotoxin (HPLC-verified) with a linear range of 0.1-1 ng/mL.

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Immobilized Human PD-1, Fc Tag, low endotoxin (HPLC-verified) at 2 µg/mL (100 µL/well) can bind Biotinylated Human PD-L2, Fc,Avitag with a linear range of 0.5-16 ng/mL.

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

The purity of Human PD-1, Fc Tag, low endotoxin (HPLC-verified) was greater than 90% as determined by SEC-HPLC.

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Flow Cytometry assay shows that Human PD-1, Fc Tag, low endotoxin (HPLC-verified) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL.

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Immobilized Biotinylated Human PD-L1, Avitag,His Tag (recommended for biopanning) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate, can bind Human PD-1, Fc Tag, low endotoxin with a linear range of 0.1-3 ng/mL (QC tested).

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • FuncS

Unknown

Functional Studies - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

Human PD-1, Fc Tag, low endotoxin (HPLC-verified) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (HPLC-verified) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200).

SDS-PAGE - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant human PD1 protein (Fc Chimera Active) (AB221398)

SDS-PAGE using ab221398 under reducing (R) condition. The gel was stained overnight with Coomassie Blue.

주요 정보

Purity

>95% SDS-PAGE

>90% as determined by SEC-HPLC.Protein A purified.

Endotoxin 레벨

< 0.1 EU/g

발현 시스템

HEK 293 cells

Tags

Fc tag C-Terminus

Applications

HPLC, SDS-PAGE, FuncS

applications

Biologically active

Yes

Biological activity

Immobilized Human PD-L1, His Tag at 1 μg/mL ( 100 μL/well ) can bind ab221398 with a linear range of 0.1-3 ng/mL.

Accession

Q15116

Animal free

No

Carrier free

No

Species

Human

Reconstitution

Reconstitute at 400 µg/mL in water

보관 버퍼

pH: 7.4 Constituents: PBS, 5% Trehalose

storage-buffer

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "HPLC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

제품 세부 정보

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

서열 정보

[{"sequence":"LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ","proteinLength":"Fragment","predictedMolecularWeight":"42.6 kDa","actualMolecularWeight":null,"aminoAcidEnd":167,"aminoAcidStart":25,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q15116","tags":[{"tag":"Fc","terminus":"C-Terminus"}]}]

특성 및 보관 정보

제형
Lyophilized
배송 시 보관 조건
Blue Ice
적절한 단기 보관 조건
-80°C
적절한 장기 보관 조건
-80°C
보관 정보
Avoid freeze / thaw cycle
True

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1's expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1's regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.

일반 정보

기능

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).

Post-translational modifications

Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation (PubMed:30487606). Ubiquitinated via 'Lys-48'-linked polyubiquitin chains (PubMed:30487606). Deubiquitinated and thus stabilized by USP5 (PubMed:37208329).. Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding (PubMed:31754127, PubMed:32184441). Phosphorylation at Tyr-248 by FYN promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed:32184441). Phosphorylation at Thr-234 promotes the recruitment of the deubiquitinase USP5 (PubMed:37208329).. N-glycosylation at Asn-58 contains at least two N-acetylglucosamine units and one fucose (PubMed:28165004). N-glycosylation does not affect binding to nivolumab drug (PubMed:28165004).

제품 프로토콜

타겟 정보

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).
See full target information PDCD1

제품이 사용된 논문 (1)

Recent publications for all applications. Explore the 전체 목록 and refine your search

Journal of the National Cancer Institute 115:1392-1403 PubMed37389416

2023

The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Cera Nieto,Bettina Miller,Nathaniel Alzofon,Tugy Chimed,Jack Himes,Molishree Joshi,Karina Gomez,Farshad N Chowdhury,Phuong N Le,Alice Weaver,Hilary Somerset,J Jason Morton,Jing H Wang,Xiao-Jing Wang,Dexiang Gao,Kirk Hansen,Stephen B Keysar,Antonio Jimeno
제품이 사용된 논문 모두 보기

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com